Studies involving companion diagnostics (CDx)
Published:
|
Updated:
Changes
- : Updated section on how to submit a notification with information about cover letter.
Information regarding performance studies involving companion diagnostics (CDx) which require a notification to NOMA, including how to submit a notification and when you will receive a decision.
Page contents
Performance studies involving companion diagnostics (CDx) using only left-over samples, as described in IVDR Article 58 (2), must be notified to NOMA. Performance studies that involve interventions or other risks for the subjects require an application to NOMA. Information on how to submit an application can be found on our website Performance studies which require an application.
How to submit a notification?
Until Eudamed is available, the notification must be submitted by e-mail to kki@noma.no. The subject heading should include “Notification of CDx performance study using left-over samples” and the name of the sponsor and the device. The documentation to be submitted with the notification is listed below:
Notification form
The notification form (‘Application-Notification form’) must be completed and signed. Appendices for part 3, 4 and 5 of the notification form is used if necessary.
Cover letter
The cover letter should provide a description of the performance study and information on the development phase. If the study is a combined study, information should be given on the relation of the performance study to the clinical trial of the medicinal product. Please provide information on whether the application for the clinical trial of the medicinal product has already been submitted to NOMA.
A separate application must be submitted to the Norwegian Ethics Committees for Clinical Trials on Medicinal Products and Medical Devices (REK KULMU) using the REK-portal. For more information, see REK KULMUs website.
Forms for notification
When will I recive a decision?
The sponsor will receive a confirmation from NOMA that the notification has been received. The notification will not be further processed by NOMA, and the study may commence when the confirmation from NOMA has been received. It is a prerequisite that REK KULMU has not issued a negative opinion.
EU regulations on medical devices
Contact us
Unit for medical devices - development and notified body
Questions regarding clinical trials, classification and innovation guidance